Economic growth has slowed in China, volume-based pricing (VBP) is affecting overseas companies’ abilities to compete on a level playing and systemic state support at high levels is offered to the local industry. At the same time, the government has set targets for more home grown medtech players to become established among the leading global companies by revenues.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?